Immunogy Q&A session with Tomo - LCR-BCCRC/LCR-BCCRC.github.io GitHub Wiki

Questions from the bioinformatics team

Gerben

  1. How do LAG3+ and FOXP3+ Tregs differ in terms of functionality and origin?
  2. According to you, what are the most promising therapeutic targets in the ME of cHL or other types of HL? Since these targets are (presumably) not tumor-specific, are side effects a major concern?

Helena

  1. In single-cell FL samples we see patient specific malignant B-cells and normal B-cells, which are present in all samples/patients. Why is the malignant B-cell sample specific but not the normal B-cells?
  2. in cHL, does the proportion of different cell types correlated with the stage of the disease?

Yifan

  1. Are the coexpression patterns of the cluster of differential(CD) antigens important in influencing the proportion of TME? When two or more CD antigens are present on the same cell type, are there any interactions between them?

Stacy

  1. Why are CD4 cells considered "more important" than CD8 cells in Hodgkin Lymphoma?

  2. What is the role of plasmacytoid dendritic cells (pDCs) in HL and are they the same as DCs?

  3. What is the most likely evolutionary path that caused HRS cells to lose their B-cell identity?

Tomo's answers